GLGema María Lledó-Ibáñez

Gema María Lledó-Ibáñez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gema María Lledó-Ibáñez has a total of 159 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Quantitative nailfold videocapillaroscopy is associated with disease activity in idiopathic inflammatory myopathies: the CapIAMI registry

    by Jorge Álvarez-Troncoso, Gema María Lledó-Ibáñez, Elena Martínez-Robles, Sebastián Molina-Ríos, Eiman Soliman, Diana-Cristina Varela, Tânia Santiago, Luis Saez-Comet, Miguel Antonio Mesa Navas, Franklin René Uguña Sari, et al.

    Objective. To assess whether quantitative nailfold videocapillaroscopy (NVC) findings are associated with clinician-assessed disease activity in idiopathic inflammatory myopathies (IIM), and how this association varies with Raynaud phenomenon (RP) status and IIM subtype.Methods. Cross-sectional analysis of the CapIAMI registry: 413 adults with IIM (2017 EULAR/ACR criteria) from 27 centres in 9 countries. NVC was performed regardless of RP status and quantified centrally with a validated deep-learning platform; incomplete laboratory panels were multiply imputed so all patients contributed. Associations with activity were examined by univariate comparison, logistic regression and Random Forest, with prespecified analyses by IIM subtype and RP status.Results. Disease was active in 265/413 patients (64.2%). Active disease was associated with lower capillary density, more giant capillaries, more microhaemorrhages, and more abnormal (neoangiogenic) shapes (all p<0.01). With all 413 patients included using multiple imputation, NVC alone and the laboratory panel discriminated similarly (AUC 0.66 vs 0.63, DeLong p=0.48); a non-linear model using both reached 0.77 and exceeded the panel (Holm p<0.001). Activity prevalence and NVC severity differed across IIM subtypes (both p<0.05). Only 117/413 (28.3%) had documented RP, yet 36% of RP-negative patients showed a scleroderma-spectrum pattern. NVC severity also tracked the number of active organ domains.Conclusion. Quantitative NVC findings are associated with clinician-assessed disease activity in IIM, and both the magnitude and pattern of this association vary by IIM subtype and RP status. Microvascular abnormalities are detectable in many RP-negative patients, supporting broader consideration of NVC in IIM beyond those presenting with RP.

  • Decreasing prevalence and cumulative incidence of scleroderma renal crisis over time: associated factors identified from the RESCLE registry

    by Xavier Pla-Salas, Carles Tolosa-Vilella, Maria Baldà-Masmiquel, Alfredo Guillén-Del-Castillo, Manuel Rubio-Rivas, Ana Argibay-Filgueira, Adela Marín-Ballvé, Ignasi Rodríguez-Pintó, Eduardo Callejas-Moraga, Dolores Colunga-Argüelles, et al.

    Objectives: To determine the prevalence and incidence of scleroderma renal crisis (SRC) in patients with SSc over two time periods and to identify factors influencing potential epidemiological changes. Methods: A total of 1939 SSc patients were categorized based on their diagnostic date. The ‘historical cohort’ (HC) included patients diagnosed before 31 December 2002, while the ‘contemporary cohort’ (CC) included those diagnosed afterwards. Epidemiological differences in SRC between both cohorts were investigated in the overall SSc series, and according to cutaneous subsets and antibody profile. If differences were present, the factors involved were assessed. Results: Forty-four patients developed SRC (prevalence rate: 2.3%), first-year incidence: 2.09 events per 100 person-years. Patients with diffuse cutaneous subset (dcSSc) (8.1%), anti-RNA polymerase III positive antibodies (12.0%) or anti-topo I positive antibodies (4.3%) had a higher prevalence of SRC than those with limited cutaneous subset (lcSSc) (0.9%) or anti-centromere-positive antibodies (0.7%). SRC prevalence decreased over time (HC vs CC) in the overall SSc series (3.7% vs 1.3%; P = 0.001), definite-SSc cohort (3.9% vs 1.4%; P = 0.002) and lcSSc (1.8% vs 0.3%; P = 0.013), but not in dcSSc or by antibody profile. Factors independently associated with the CC included older age at SSc diagnosis, increased prevalence of early SSc and very early SSc subsets, tobacco exposure and higher medication use of calcium channel blockers, renin–angiotensin–aldosterone system inhibitors, specific vasodilators and immunosuppressants. Conclusions: This study provides compelling evidence of a significant decline in SRC prevalence and cumulative incidence over time in SSc patients, particularly in definite-SSc patients and lcSSc patients. Factors associated with the CC are described.


  • Top Cited Papers
    Open Access

    CAPI-Detect: machine learning in capillaroscopy reveals new variables influencing diagnosis

    by Gema M Lledó-Ibáñez, Luis Sáez Comet, Mayka Freire Dapena, Miguel Mesa Navas, Miguel Martín Cascón, Alfredo Guillén del Castillo, Carmen Pilar Simeon, Elena Martinez Robles, José Todolí Parra, Diana Cristina Varela, et al.

    Objectives: Nailfold videocapillaroscopy (NVC) is the gold standard for diagnosing SSc and differentiating primary from secondary RP. The CAPI-Score algorithm, designed for simplicity, classifies capillaroscopy scleroderma patterns (CSPs) using a limited number of capillary variables. This study aims to develop a more advanced machine learning (ML) model to improve CSP identification by integrating a broader range of statistical variables while minimizing examiner-related bias. Methods: A total of 1780 capillaroscopies were randomly and blindly analysed by three to four trained observers. Consensus was defined as agreement among all but one observer (partial consensus) or unanimous agreement (full consensus). Capillaroscopies with at least partial consensus were used to train ML-based classification models using CatBoost software, incorporating 24 capillary architecture-related variables extracted via automated NVC analysis. Validation sets were employed to assess model performance. Results: Of the 1490 capillaroscopies classified with consensus, 515 achieved full consensus. The model, evaluated on partial and full consensus datasets, achieved 0.912, 0.812 and 0.746 accuracy for distinguishing SSc from non-SSc, among SSc patterns, and between normal and non-specific patterns, respectively. When evaluated on full consensus only, accuracy improved to 0.910, 0.925 and 0.933. CAPI-Detect outperformed CAPI-Score, revealing novel capillary variables critical to ML-based classification. Conclusions: CAPI-Detect, an ML-based model, provides an unbiased, quantitative analysis of capillary structure, shape, size and density, significantly improving capillaroscopic pattern identification.


  • Antisynthetase Syndrome

    by Jorge Álvarez Troncoso, Gema M. Lledó-Ibáñez, Estíbaliz Ruiz-Ortiz, Mariana Benegas, Fernanda Hernández, Sergio Prieto-González

  • Polymyositis

    by Gema M. Lledó-Ibáñez, Jorge Álvarez Troncoso, Sergio Prieto-González

  • Granulomatous Myositis

    by Carlos Hernández Cerón, Pablo López Mato, Gema M. Lledó-Ibáñez, Sergio Prieto-González

  • Systemic Sclerosis

    by Gema Maria Lledó, Gerard Espinosa

  • Open Access

    Persistence of a SARS-CoV-2 T-cell response in patients with long COVID and lung sequelae after COVID-19

    by Tamara Cruz, Núria Mendoza, Gema M. Lledó, Lídia Perea, Núria Albacar, Alvar Agustí, Jacobo Sellares, Oriol Sibila, Rosa Faner

    Most individuals fully recover after suffering coronavirus disease 2019 (COVID-19), but a subset of patients present persistent post-disease abnormalities, including 1) long COVID, defined as the persistence (>2 months) of symptoms 3 months after the onset of COVID-19 that cannot be explained by an alternative diagnosis [1]; and 2) chronic pulmonary sequelae, defined as abnormal lung function and/or lung structure [2–5]. The mechanisms underlying long COVID or pulmonary sequelae remain unknown, but both have been associated with persistent inflammation [6, 7], including alterations in the blood CD8+ T-cells and a sustained virus-specific T-cell response [8–10]. Additionally, recent studies suggest that the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in some organs may drive chronic activation of B-cells and inflammation [6, 11, 12].


  • Open Access

    Anti-dsDNA B-Cell ELISpot as a Monitoring and Flare Prediction Tool in SLE Patients

    by Albert Pérez-Isidro, Marc Xipell, Arturo Llobell, Noemí De Moner, Gema M. Lledó, Ricard Cervera, Sergio Prieto-González, Luis F. Quintana, Gerard Espinosa, Mila García-Ormaechea, et al.

    Anti-dsDNA autoantibodies quantification and complement levels are widely used to monitor disease activity in systemic lupus erythematosus (SLE). However, better biomarkers are still needed. We hypothesised whether the dsDNA antibody-secreting B-cells could be a complementary biomarker in disease activity and prognosis of SLE patients. Fifty-two SLE patients were enrolled and followed for up to 12 months. Additionally, 39 controls were included. An activity cut-off (comparing active and non-active patients according to clinical SLEDAI-2K) was established for SLE-ELISpot, chemiluminescence and Crithidia luciliae indirect immunofluorescence tests (≥11.24, ≥374.1 and ≥1, respectively). Assays performances together with complement status were compared regarding major organ involvement at the inclusion and flare-up risk prediction after follow-up. SLE-ELISpot showed the best performance in identifying active patients. High SLE-ELISpot results were associated with haematological involvement and, after follow-up, with an increased hazard ratio for disease flare-up (3.4) and especially renal flare (6.5). Additionally, the combination of hypocomplementemia and high SLE-ELISpot results increased those risks up to 5.2 and 32.9, respectively. SLE-ELISpot offers complementary information to anti-dsDNA autoantibodies to evaluate the risk of a flare-up in the following year. In some cases, adding SLE-ELISpot to the current follow-up protocol for SLE patients can improve clinicians’ personalised care decisions.


  • Open Access

    Patient Care Pathways for Pregnancy in Rare and Complex Rheumatic Diseases: Results From an International Survey

    by Chiara Tani, Dina Zucchi, Elisa Bellis, Mehret Birru Talabi, Charlotte Frise, Guilherme Ramires de Jesús, Hege Svean Koksvik, Gema Maria Lledó, Arsène Mekinian, Diana Marinello, et al.

    Objective: To map existing organizational care pathways in clinical centers of expertise that care for pregnant women affected by rare and complex connective tissue diseases (rcCTDs).Methods: An international working group composed of experts in the field of pregnancy in rcCTDs co-designed a survey focused on organizational aspects related to the patient’s pathway before, during, and after pregnancy. The survey was distributed to subject experts through referral sampling.Results: Answers were collected from 69 centers in 21 countries. Patients with systemic lupus erythematosus and/or antiphospholipid syndrome were followed by more than 90% of centers, whereas those with disorders such as IgG4-related diseases were rarely covered. In the majority of centers, a multidisciplinary team was involved, including an obstetrician/gynecologist in 91.3% of cases and other healthcare professionals less frequently. Respondents indicated that 96% of the centers provided routine pre-pregnancy care, whereas the number of patient visits during pregnancy varied across centers. A formalized care pathway was described in 49.2% of centers, and 20.3% of centers had a predefined protocol for the monitoring of pregnant patients. Access to therapies during pregnancy also was heterogeneous among different centers.Conclusion: In international referral centers, a high level of care is provided to patients with rcCTDs before, during, and after pregnancy. No significant discrepancies were found between European and non-European countries. However, this work highlights a potential benefit to streamlining the care approaches across countries to optimize pregnancy and perinatal outcomes among patients with rcCTDs.